Gland Pharma Share Price
Sector: Biotechnology & Drugs
1498.50 +14.35 (0.97%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1487.00
Today’s High
1519.60
52 Week Low
1200.00
52 Week High
2220.95
1498.30 +14.40 (0.97%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1488.10
Today’s High
1520.00
52 Week Low
1277.80
52 Week High
2220.95
Key Metrics
- Market Cap (In Cr) 24688.75
- Beta 0.61
- Div. Yield (%) 1.35
- P/B 2.8
- TTM P/E 41.61
- Peg Ratio -3.7
- Sector P/E 24.5
- Open Price 1496
- Prev Close 1484.15
Gland Pharma Analysis
Price Analysis
-
1 Week3.76%
-
3 Months0.36%
-
6 Month-16.32%
-
YTD-16.6%
-
1 Year-16.6%
Risk Meter
- 31% Low risk
- 31% Moderate risk
- 31% Balanced Risk
- 31% High risk
- 31% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 4
- 4
- Buy
- 0.00
- 0.00
- 0.00
- 0.00
- Hold
- 1
- 1
- 1
- 1
- Sell
- 3
- 3
- 3
- 3
- Strong Sell
- 2
- 2
- 2
- 2
- Total
- 10
- 10
- 10
- 10
Gland Pharma News
Gland Pharma Q4 results: Profit dips 3% YoY to ₹187 cr; 1800% dividend announced
2 min read . 20 May 2025ICICI Pru MF buys 4 lakh shares of THIS pharma co despite 10% dip in April
2 min read . 16 Apr 2025Pharma stocks fall up to 5% as Donald Trump to announce pharma tariffs
1 min read . 09 Apr 2025Pharma shares rise up to 13% on Trump's tariff exemption; Gland Pharma lead gain
3 min read . 03 Apr 2025Gland Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 5664.72
- Selling/ General/ Admin Expenses Total
- 2012.94
- Depreciation/ Amortization
- 344.57
- Other Operating Expenses Total
- 55.4
- Total Operating Expense
- 4676.22
- Operating Income
- 988.51
- Net Income Before Taxes
- 1132.54
- Net Income
- 772.46
- Diluted Normalized EPS
- 46.88
- Period
- 2024
- Total Assets
- 10661.25
- Total Liabilities
- 1937.4
- Total Equity
- 8723.84
- Tangible Book Valueper Share Common Eq
- 508.13
- Period
- 2024
- Cashfrom Operating Activities
- 996.8
- Cashfrom Investing Activities
- -1756.91
- Cashfrom Financing Activities
- -799.42
- Net Changein Cash
- -1551.81
- Period
- 2023
- Total Revenue
- 3624.6
- Selling/ General/ Admin Expenses Total
- 810
- Depreciation/ Amortization
- 146.74
- Other Operating Expenses Total
- 9.73
- Total Operating Expense
- 2802.95
- Operating Income
- 821.65
- Net Income Before Taxes
- 1054.58
- Net Income
- 781.04
- Diluted Normalized EPS
- 50.26
- Period
- 2023
- Total Assets
- 8777.54
- Total Liabilities
- 818.81
- Total Equity
- 7958.72
- Tangible Book Valueper Share Common Eq
- 482.51
- Period
- 2023
- Cashfrom Operating Activities
- 363.97
- Cashfrom Investing Activities
- 1208.19
- Cashfrom Financing Activities
- 14.92
- Net Changein Cash
- 1590.08
- Period
- 2022
- Total Revenue
- 4400.71
- Selling/ General/ Admin Expenses Total
- 694.61
- Depreciation/ Amortization
- 110.3
- Other Operating Expenses Total
- 3.79
- Total Operating Expense
- 3000.67
- Operating Income
- 1400.03
- Net Income Before Taxes
- 1618.55
- Net Income
- 1211.66
- Diluted Normalized EPS
- 73.65
- Period
- 2022
- Total Assets
- 7833.62
- Total Liabilities
- 676
- Total Equity
- 7157.62
- Tangible Book Valueper Share Common Eq
- 434.87
- Period
- 2022
- Cashfrom Operating Activities
- 790.77
- Cashfrom Investing Activities
- -1002.62
- Cashfrom Financing Activities
- 34.9
- Net Changein Cash
- -173.64
- Period
- 2021
- Total Revenue
- 3462.88
- Selling/ General/ Admin Expenses Total
- 590.16
- Depreciation/ Amortization
- 98.78
- Other Operating Expenses Total
- 0.12
- Total Operating Expense
- 2259.43
- Operating Income
- 1203.45
- Net Income Before Taxes
- 1334.81
- Net Income
- 996.96
- Diluted Normalized EPS
- 62.99
- Period
- 2021
- Total Assets
- 6496.08
- Total Liabilities
- 592.84
- Total Equity
- 5903.24
- Tangible Book Valueper Share Common Eq
- 360.85
- Period
- 2021
- Cashfrom Operating Activities
- 604.93
- Cashfrom Investing Activities
- -1524
- Cashfrom Financing Activities
- 1238.46
- Net Changein Cash
- 322.97
- Period
- 2020
- Total Revenue
- 2633.24
- Selling/ General/ Admin Expenses Total
- 514.31
- Depreciation/ Amortization
- 94.59
- Other Operating Expenses Total
- 4.31
- Total Operating Expense
- 1772.36
- Operating Income
- 860.88
- Net Income Before Taxes
- 992.87
- Net Income
- 772.86
- Diluted Normalized EPS
- 46.5
- Period
- 2020
- Total Assets
- 4086.04
- Total Liabilities
- 439.8
- Total Equity
- 3646.23
- Tangible Book Valueper Share Common Eq
- 223.31
- Period
- 2020
- Cashfrom Operating Activities
- 700.94
- Cashfrom Investing Activities
- -766.08
- Cashfrom Financing Activities
- -6.87
- Net Changein Cash
- -66.91
- Period
- 2019
- Total Revenue
- 2044.2
- Selling/ General/ Admin Expenses Total
- 432.64
- Depreciation/ Amortization
- 82.12
- Other Operating Expenses Total
- 1.05
- Total Operating Expense
- 1439.82
- Operating Income
- 604.38
- Net Income Before Taxes
- 686.28
- Net Income
- 451.86
- Diluted Normalized EPS
- 28.48
- Period
- 2019
- Total Assets
- 3523.55
- Total Liabilities
- 661.55
- Total Equity
- 2862
- Tangible Book Valueper Share Common Eq
- 175.28
- Period
- 2019
- Cashfrom Operating Activities
- 185.26
- Cashfrom Investing Activities
- -314.14
- Cashfrom Financing Activities
- -3.12
- Net Changein Cash
- -136.44
- Period
- 2024-12-31
- Total Revenue
- 1384.05
- Selling/ General/ Admin Expenses Total
- 397.52
- Depreciation/ Amortization
- 96.33
- Other Operating Expenses Total
- 163.87
- Total Operating Expense
- 1120.42
- Operating Income
- 263.63
- Net Income Before Taxes
- 299.3
- Net Income
- 204.69
- Diluted Normalized EPS
- 12.42
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 1405.83
- Selling/ General/ Admin Expenses Total
- 375.19
- Depreciation/ Amortization
- 93.83
- Other Operating Expenses Total
- 158.13
- Total Operating Expense
- 1202.6
- Operating Income
- 203.23
- Net Income Before Taxes
- 256.78
- Net Income
- 163.53
- Diluted Normalized EPS
- 9.93
- Period
- 2024-09-30
- Total Assets
- 10866.89
- Total Liabilities
- 2078.89
- Total Equity
- 8788
- Tangible Book Valueper Share Common Eq
- 511.24
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 643.63
- Cashfrom Investing Activities
- 2212.64
- Cashfrom Financing Activities
- -402.74
- Net Changein Cash
- 2463.02
- Period
- 2024-06-30
- Total Revenue
- 1401.71
- Selling/ General/ Admin Expenses Total
- 402.04
- Depreciation/ Amortization
- 91.96
- Other Operating Expenses Total
- 171.01
- Total Operating Expense
- 1229.28
- Operating Income
- 172.44
- Net Income Before Taxes
- 218.24
- Net Income
- 143.76
- Diluted Normalized EPS
- 8.73
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1537.45
- Selling/ General/ Admin Expenses Total
- 409.49
- Depreciation/ Amortization
- 92.61
- Other Operating Expenses Total
- 169.93
- Total Operating Expense
- 1271.41
- Operating Income
- 266.04
- Net Income Before Taxes
- 298.23
- Net Income
- 192.42
- Diluted Normalized EPS
- 11.67
- Period
- 2024-03-31
- Total Assets
- 10661.25
- Total Liabilities
- 1937.4
- Total Equity
- 8723.84
- Tangible Book Valueper Share Common Eq
- 508.13
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 996.8
- Cashfrom Investing Activities
- -1756.91
- Cashfrom Financing Activities
- -799.42
- Net Changein Cash
- -1551.81
- Period
- 2023-12-31
- Total Revenue
- 1545.16
- Selling/ General/ Admin Expenses Total
- 409.37
- Depreciation/ Amortization
- 105.34
- Other Operating Expenses Total
- 180.16
- Total Operating Expense
- 1294.11
- Operating Income
- 251.05
- Net Income Before Taxes
- 283.16
- Net Income
- 191.86
- Diluted Normalized EPS
- 11.65
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Gland Pharma Technical
Moving Average
SMA
- 5 Day1450.33
- 10 Day1432.79
- 20 Day1435.79
- 50 Day1502.84
- 100 Day1570.46
- 300 Day1698.19
Gland Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Syngene International
- 628.65
- -13.3
- -2.07
- 960
- 598.55
- 25285.79
- J B Chemicals And Pharmaceutical
- 1704
- 40.05
- 2.41
- 2029
- 1303
- 26474.95
- Gland Pharma
- 1498.5
- 14.35
- 0.97
- 2220.95
- 1200
- 24688.75
- Wockhardt
- 1325
- -34.35
- -2.53
- 1678.6
- 489.2
- 21535.59
- Eris Lifesciences
- 1463.05
- 19.6
- 1.36
- 1593
- 815.5
- 20043.28
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Syngene International
- 54.97
- 5.48
- 13.02
- 15.03
- J B Chemicals And Pharmaceutical
- 39.63
- 7.47
- 20.84
- 16.36
- Gland Pharma
- 31.34
- 2.77
- 14.89
- 22.92
- Wockhardt
- -
- 6.08
- -10.63
- -12.7
- Eris Lifesciences
- 50.62
- 7.7
- 20.71
- 24.96
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 20-May-25
- Audited Results & Final Dividend
- 03-Feb-25
- Quarterly Results
- 04-Nov-24
- Quarterly Results
- 06-Aug-24
- Quarterly Results
- 22-May-24
- Audited Results & Final Dividend
- 14-Feb-24
- Quarterly Results
- 06-Nov-23
- Quarterly Results
- 07-Aug-23
- Quarterly Results
- 18-May-23
- Audited Results & A.G.M.
- 23-Jan-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 01-Apr-25
- 28-Feb-25
- POM
- 11-Mar-25
- 07-Feb-25
- POM
- 10-Dec-24
- 08-Nov-24
- POM
- 30-Aug-24
- 22-May-24
- AGM
- 20-Nov-23
- 19-Oct-23
- POM
- 31-Aug-23
- 01-Aug-23
- AGM
- 08-Mar-23
- 06-Feb-23
- POM
- 30-Aug-22
- 19-May-22
- AGM
- 22-Apr-22
- 21-Mar-22
- POM
- 26-Aug-21
- 17-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 22-May-24
- 16-Aug-24
- 16-Aug-24
- 20


